Pharming Group NV (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR), a Netherlands-based global biopharmaceutical company, announced on Friday that it has received approval from the US Food and Drug Administration (FDA) for the company's Joenja (leniolisib) to treat activated phosphoinositide 3-kinase delta (PI3K delta) syndrome (APDS) in adult and paediatric patients 12 years of age and older.
Joenja, an oral, selective PI3K delta inhibitor, is the first and only treatment approved in the US for APDS, a rare and progressive primary immunodeficiency.
The FDA evaluated the New Drug Application (NDA) for Joenja under priority review and has approved the drug based on findings from a multinational, triple-blind, placebo-controlled, randomised Phase II/III clinical trial, which evaluated efficacy and safety in 31 patients diagnosed with APDS aged 12 years and older.
Joenja is expected to launch in the US in early April and will be available for shipment in mid-April.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT